Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
UK: A recent study published in BMJ Medicine found that more caffeine in the blood can reduce the risk of type 2 diabetes and obesity. more...
Read Full NewsNew phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing
Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.
Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D
Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis
1.
Getting More Done With Less Blood.
2.
New imaging solution could help improve survival for patients with recurring prostate cancer
3.
A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.
4.
Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers
5.
Taking Charge of Your Cancer Journey.
1.
Exploring Innovative Approaches to Esophageal Cancer Treatment
2.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
3.
Hemophilia: Pathophysiology, Genetics, and Treatment Advances
4.
Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results
5.
Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge